ProCE Banner Activity

Considerations From Experts on Optimal Use of Immunotherapy for Patients With Lung Cancer

Clinical Thought

Gain expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC.

Released: January 23, 2023

Share

Faculty

Julie R. Brahmer

Julie R. Brahmer, MD, MSc, FASCO

Marilyn Meyerhoff Professor of Oncology
Co-Director, Thoracic Oncology
Co-Director, Upper Aerodigestive
Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Co-Leader of the Cancer Immunology Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Regeneron Pharmaceuticals, Inc.

Program Director Disclosure

Program Director

Julie R. Brahmer, MD, MSc, FASCO

Marilyn Meyerhoff Professor of Oncology
Co-Director, Thoracic Oncology
Co-Director, Upper Aerodigestive
Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Co-Leader of the Cancer Immunology Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Julie R. Brahmer, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Janssen, Lilly, Merck, Regeneron, Sanofi.

Faculty Disclosure

Primary Author

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB, BCH, MHS: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Kaleido Biosciences, Merck, NGM Pharmaceuticals, Novartis, Pfizer, Roche/Genentech, Takeda; researcher: Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Mirati, Novartis, Roche/Genentech.

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AstraZeneca, Cullinan Oncology, C4 Therapeutics, Daiichi Sankyo, Eli Lilly, Janssen, Sanofi, Taiho, Takeda.